These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 25982283)

  • 1. IMP3 promotes stem-like properties in triple-negative breast cancer by regulating SLUG.
    Samanta S; Sun H; Goel HL; Pursell B; Chang C; Khan A; Greiner DL; Cao S; Lim E; Shultz LD; Mercurio AM
    Oncogene; 2016 Mar; 35(9):1111-21. PubMed ID: 25982283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IMP3 promotes TNBC stem cell property through miRNA-34a regulation.
    Huang QD; Zheng SR; Cai YJ; Chen DL; Shen YY; Lin CQ; Hu XQ; Wang XH; Shi H; Guo GL
    Eur Rev Med Pharmacol Sci; 2018 May; 22(9):2688-2696. PubMed ID: 29771420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of epithelial–mesenchymal transition and stem cell markers in intrinsic subtypes of breast cancer.
    Pomp V; Leo C; Mauracher A; Korol D; Guo W; Varga Z
    Breast Cancer Res Treat; 2015 Nov; 154(1):45-55. PubMed ID: 26467042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IMP3 Stabilization of WNT5B mRNA Facilitates TAZ Activation in Breast Cancer.
    Samanta S; Guru S; Elaimy AL; Amante JJ; Ou J; Yu J; Zhu LJ; Mercurio AM
    Cell Rep; 2018 May; 23(9):2559-2567. PubMed ID: 29847788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IMP3 expression is associated with epithelial-mesenchymal transition in breast cancer.
    Su P; Hu J; Zhang H; Li W; Jia M; Zhang X; Wu X; Cheng H; Xiang L; Zhou G
    Int J Clin Exp Pathol; 2014; 7(6):3008-17. PubMed ID: 25031719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of IMP3 expression as a determinant of chemosensitivity in triple-negative breast cancer.
    Ohashi R; Sangen M; Namimatsu S; Yanagihara K; Yamashita K; Sakatani T; Takei H; Naito Z
    Pathol Res Pract; 2017 Sep; 213(9):1160-1165. PubMed ID: 28756977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of IMP3 immunohistochemical expression in triple negative breast cancer.
    Sjekloča N; Tomić S; Mrklić I; Vukmirović F; Vučković L; Lovasić IB; Maras-Šimunić M
    Medicine (Baltimore); 2020 Feb; 99(7):e19091. PubMed ID: 32049813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IMP2 and IMP3 cooperate to promote the metastasis of triple-negative breast cancer through destabilization of progesterone receptor.
    Kim HY; Ha Thi HT; Hong S
    Cancer Lett; 2018 Feb; 415():30-39. PubMed ID: 29217458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.
    Walter O; Prasad M; Lu S; Quinlan RM; Edmiston KL; Khan A
    Hum Pathol; 2009 Nov; 40(11):1528-33. PubMed ID: 19695680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The involvement of insulin-like growth factor 2 binding protein 3 (IMP3) in pancreatic cancer cell migration, invasion, and adhesion.
    Pasiliao CC; Chang CW; Sutherland BW; Valdez SM; Schaeffer D; Yapp DT; Ng SS
    BMC Cancer; 2015 Apr; 15():266. PubMed ID: 25886367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IMP3 protein promotes chemoresistance in breast cancer cells by regulating breast cancer resistance protein (ABCG2) expression.
    Samanta S; Pursell B; Mercurio AM
    J Biol Chem; 2013 May; 288(18):12569-73. PubMed ID: 23539627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of IMP3 by EGFR signaling and repression by ERβ: implications for triple-negative breast cancer.
    Samanta S; Sharma VM; Khan A; Mercurio AM
    Oncogene; 2012 Nov; 31(44):4689-97. PubMed ID: 22266872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The basal-like breast carcinoma phenotype is regulated by SLUG gene expression.
    Storci G; Sansone P; Trere D; Tavolari S; Taffurelli M; Ceccarelli C; Guarnieri T; Paterini P; Pariali M; Montanaro L; Santini D; Chieco P; Bonafé M
    J Pathol; 2008 Jan; 214(1):25-37. PubMed ID: 17973239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SIX2 Mediates Late-Stage Metastasis via Direct Regulation of
    Oliphant MUJ; Vincent MY; Galbraith MD; Pandey A; Zaberezhnyy V; Rudra P; Johnson KR; Costello JC; Ghosh D; DeGregori J; Espinosa JM; Ford HL
    Cancer Res; 2019 Feb; 79(4):720-734. PubMed ID: 30606720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Inhibition of Histone Deacetylases Reverses Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer Cells through a Slug Mediated Mechanism].
    Rahimian A; Barati G; Mehrandish R; Mellati AA
    Mol Biol (Mosk); 2018; 52(3):474-481. PubMed ID: 29989579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SOX2 Promotes the Epithelial to Mesenchymal Transition of Esophageal Squamous Cells by Modulating Slug Expression through the Activation of STAT3/HIF-α Signaling.
    Gao H; Teng C; Huang W; Peng J; Wang C
    Int J Mol Sci; 2015 Sep; 16(9):21643-57. PubMed ID: 26370982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HES1 promotes breast cancer stem cells by elevating Slug in triple-negative breast cancer.
    Li X; Li Y; Du X; Wang X; Guan S; Cao Y; Jin F; Li F
    Int J Biol Sci; 2021; 17(1):247-258. PubMed ID: 33390847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of SOX2 expression delineates an end-point for paclitaxel-effectiveness in breast cancer stem cells.
    Mukherjee P; Gupta A; Chattopadhyay D; Chatterji U
    Sci Rep; 2017 Aug; 7(1):9170. PubMed ID: 28835684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of insulin-like growth factor II mRNA-binding protein 3 predicts early recurrence and poor prognosis in intrahepatic cholangiocarcinoma.
    Chen YL; Jeng YM; Hsu HC; Lai HS; Lee PH; Lai PL; Yuan RH
    Int J Surg; 2013; 11(1):85-91. PubMed ID: 23246869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VEGFA links self-renewal and metastasis by inducing Sox2 to repress miR-452, driving Slug.
    Kim M; Jang K; Miller P; Picon-Ruiz M; Yeasky TM; El-Ashry D; Slingerland JM
    Oncogene; 2017 Sep; 36(36):5199-5211. PubMed ID: 28504716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.